|
T1803 |
GNF-5
|
GNF 5 |
SARS-CoV
,
Bcr-Abl
|
|
GNF-5 is a specific non-ATP competitive inhibitor of Bcr-Abl (IC50: 0.22±0.1 uM, Wild-type Abl). It is an analog of GNF-2 with improved pharmacokinetic properties. |
|
T3196 |
GNF-7
|
GNF7 |
Bcr-Abl
,
ACK
,
AChR
|
|
GNF-7 is Bcr-Abl WT and Bcr-Abl T315I inhibitor with IC50 of 133 nM and 61 nM, respectively. |
|
T21785 |
AG957
|
|
Bcr-Abl
|
|
Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors[1]. |
|
T22553 |
Adaphostin
|
1-Adamantyl 4-((2,5-Dihydroxybenzyl)Amino)Benzoate,NSC 680410 |
Bcr-Abl
|
|
Adaphostin (NSC-680410) is a p210Bcr/Abl tyrosine kinase inhibitor with IC50 of 14 μM. |
|
T16545 |
Pivanex
|
Pivalyloxymethyl butyrate,AN-9 |
Apoptosis
,
HDAC
,
Bcr-Abl
|
|
Pivanex (Pivalyloxymethyl butyrate) is an orally active HDAC inhibitor and an antimetastatic and antiangiogenic agent. Pivanex downregulates the Bcr-Abl protein and enhances apoptosis. |
|
T26625 |
AN-019
|
NRC-AN-019,NRC-019 |
Bcr-Abl
|
|
AN-019 (NRC-019) is a Bcr-Abl kinase inhibitor with antitumor activity for the study of chronic myelogenous leukemia (CML) and breast cancer. |
|
T22378 |
Nilotinib hydrochloride
|
AMN-107 HCl |
Bcr-Abl
,
Autophagy
|
|
Nilotinib hydrochloride(AMN-107 HCl) is an orally available Bcr-Abl tyrosine kinase inhibitor with antitumor activity for modulation of neuroinflammation and cognitive deficits, and may be used in studies of chronic myel... |
|
T23128 |
PD180970
|
PD 180970 |
Bcr-Abl
,
Src
,
c-Kit
|
|
PD180970 is an inhibitor of Bcr-Abl with IC50s of 5 nM, 0.8 nM and 50 nM for the autophosphorylation of p210Bcr-Abl, Src and Kit. PD180970 can be used in studies about chronic myelogenous leukemia. |
|
T72958 |
BCR-ABL-IN-7
|
|
Bcr-Abl
|
|
BCR-ABL-IN-7 is a WT and T315I mutant ABL kinase inhibitor.BCR-ABL-IN-7 potently inhibits WT and T315I mutant ABL kinase activity.BCR-ABL-IN-7 can be used in chronic myelogenous leukemia (CML) research. |
|
T71068 |
Nilotinib dihydrochloride dihydrate
|
|
|
|
Nilotinib dihydrochloride dihydrate is a small-molecule tyrosine kinase inhibitor approved for the treatment of imatinib-resistant chronic myelogenous leukemia. |
|
T68338 |
Nilotinib hydrochloride dihydrate
|
|
|
|
Nilotinib hydrochloride dihydrate is a small-molecule tyrosine kinase inhibitor approved for the treatment of imatinib-resistant chronic myelogenous leukemia. |
|
T71144 |
Nilotinib N-oxide
|
|
|
|
Nilotinib N-oxide is a small-molecule tyrosine kinase inhibitor approved for the treatment of imatinib-resistant chronic myelogenous leukemia. |
|
T10488 |
BCR-ABL-IN-1
|
|
Bcr-Abl
|
|
BCR-ABL-IN-1 is a BCR-ABL tyrosine kinase inhibitor (pIC50: 6.46) and may be used in the research of chronic myelogenous leukemia. |
|
T22859 |
Imatinib hydrochloride
|
|
Others
|
|
Imatinib is a multi-target inhibitor of v-Abl, c-Kit, and PDGFR (IC50: 0.6 μM, 0.1 μM, and 0.1 μM, respectively). Imatinib is used to treat chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs), and... |
|
T60927 |
Ranimustine
|
|
|
|
Ranimustine (MCNU) can be used for polycythemia vera and chronic myelogenous leukemia research, which is a nitrosourea alkylating agent [1] [3] [4]. |
|
T71313 |
BVB-808
|
|
|
|
BVB-808 is a selective Jak2 type 1 inhibitor. Janus kinases are critical components of signaling pathways that regulate hematopoiesis. Mutations of the non-receptor tyrosine kinase JAK2 are found in many BCR-ABL-negative... |
|
T78904 |
Anticancer agent 110
|
|
Apoptosis
|
|
Anticancer Agent 110 exhibits potent in vitro anti-leukemia activity, demonstrating high cytotoxicity against K-562 lineage chronic myelogenous leukemia cells at nanomolar concentrations. It induces DNA damage and subseq... |
